Ligand Pharmaceuticals INC 8-K filings

Ligand Pharmaceuticals announced robust second-quarter 2026 financial results, highlighted by a 32% year-over-year increase in royalty revenue and the successful acquisition of XOMA Royalty.

Ligand Pharmaceuticals has finalized its acquisition of XOMA Royalty Corporation for approximately $739 million, significantly expanding its biopharmaceutical royalty asset portfolio.

Ligand Pharmaceuticals has finalized a $700 million private offering of 0.00% convertible senior notes due 2031.

Ligand Pharmaceuticals Incorporated announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and approval of an amended stock incentive plan.

Ligand Pharmaceuticals Incorporated announced an amendment to its Agreement and Plan of Merger with XOMA Royalty Corporation, adding a new holding company as a party to the agreement.

Ligand Pharmaceuticals announced strong first quarter 2026 financial results, driven by a 56% year-over-year increase in royalty revenue, and reaffirmed its full-year guidance, incorporating the anticipated contribution from the pending acquisition of XOMA Royalty.

Ligand Pharmaceuticals has issued a termination notice for its TR-Beta program license with Viking Therapeutics, citing a material breach of contract.

Ligand Pharmaceuticals announced its definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million in cash and stock, significantly expanding its royalty portfolio.

Ligand Pharmaceuticals reported robust fourth quarter and full year 2025 financial results, driven by significant royalty revenue growth and successful product launches, while reaffirming its 2026 financial guidance.

Ligand Pharmaceuticals announced it has posted details of its private placement investment in Athira Pharma, Inc. on its investor relations and social media channels.

Ligand Pharmaceuticals reported robust third-quarter 2025 financial results, driven by a 47% increase in royalty revenue, leading to a second upward revision of its full-year financial guidance.

Ligand Pharmaceuticals Inc. has amended its credit agreement, extending the maturity date to September 2028 and increasing financial covenant thresholds, enhancing operational flexibility.

Ligand Pharmaceuticals completed a $460 million private offering of 0.75% convertible senior notes due 2030, enhancing financial flexibility and managing potential dilution.

Ligand Pharmaceuticals announced a proposed private offering of $400 million in convertible senior notes due 2030, with proceeds intended for dilution mitigation, share repurchases, and general corporate purposes.

Ligand Pharmaceuticals reported robust Q2 2025 financial results, driven by a 57% surge in royalty revenue, leading to an upward revision of its full-year 2025 financial guidance.

Ligand Pharmaceuticals announced the completion of its merger with Channel Therapeutics, forming Pelthos Therapeutics Inc., which will commence trading on the NYSE American under PTHS and plans to launch its novel drug ZELSUVMI in July 2025.

Ligand Pharmaceuticals Incorporated announced the results of its 2025 Annual Meeting of Stockholders, confirming the election of all eight director nominees, the ratification of Ernst & Young LLP as its independent auditor, and the approval of executive officer compensation.

Ligand Pharmaceuticals announces a 46% increase in total revenues for Q1 2025, driven by a 44% surge in royalty revenue and increased Captisol sales, while reaffirming its 2025 financial guidance.

Ligand Pharmaceuticals' subsidiary, Pelthos Therapeutics, will merge with Channel Therapeutics, supported by a $50 million equity investment, to focus on commercializing ZELSUVMI and advancing pain treatment programs.

Ligand Pharmaceuticals announces robust financial performance for 2024, highlighted by a 28% increase in royalty revenue and reiterates its 2025 financial guidance.

Ligand Pharmaceuticals leads a $75 million royalty financing round for Castle Creek Biosciences to support the Phase 3 clinical trial of D-Fi, a gene therapy for dystrophic epidermolysis bullosa (DEB).

Ligand Pharmaceuticals reported a strong third quarter in 2024, driven by increased royalty revenue, leading to an upward revision of their full-year revenue and earnings guidance.

Ligand Pharmaceuticals announced a strong second quarter in 2024, with significant revenue growth driven by increased royalties and milestone payments.

Ligand Pharmaceuticals announced the departure of its President and Chief Operating Officer, Matthew Korenberg, with a transition plan that includes severance and a consulting agreement.

Ligand Pharmaceuticals has completed its acquisition of APEIRON Biologics for $100 million in cash, gaining royalty rights to the cancer drug QARZIBA.

Ligand Pharmaceuticals has increased its revolving credit facility from $75 million to $125 million through an amendment to its existing credit agreement.

Ligand Pharmaceuticals is set to acquire APEIRON Biologics for $100 million, gaining royalty rights to the cancer drug QARZIBA and increasing its 2024 financial outlook.

Ligand Pharmaceuticals' partner, Verona Pharma, has secured FDA approval for Ohtuvayre, a new COPD treatment, resulting in a $5.8 million milestone payment for Ligand and a potential $13.8 million payment upon commercial launch.

Ligand Pharmaceuticals is set to receive a $2 million milestone payment and royalties on net sales following the FDA approval of Merck's CAPVAXIVE vaccine, which utilizes Ligand's Pfenex technology.

Ligand Pharmaceuticals' stockholders approved an amended stock incentive plan and elected eight directors at their 2024 annual meeting on June 14, 2024.